ArticleArthritis & rheumatology (Hoboken, N.J.)2019
Treatment to Target Using Recombinant Interleukin-1 Receptor Antagonist as First-Line Monotherapy in New-Onset Systemic Juvenile Idiopathic Arthritis: Results From a Five-Year Follow-Up Study.
Nienke M Ter Haar et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
90 papers cite itlatest 60 shown
this paperpooled ittrialcites it